Article
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.
Leukemia - 1 Apr 2026
Riedhammer C, Truger M, Lee H, Leypoldt L B, Meggendorfer M, Hutter S, Müller H, Mersi J, Kadel S K, Buchwald T, Kosch R, Helal M, Afrin N, Rosenwald A, Gerhard-Hartmann E, Brioli A, Krönke J, Haferlach T, Haferlach C, Weisel K C, Neri P, Einsele H, Kortüm K M, Waldschmidt J M, Bahlis N, Weinhold N, Rasche L
Abstract excerpt
Multiple myeloma (MM) resistant to CD38 antibodies, two immunomodulatory drugs (IMiDs), two proteasome inhibitors (PIs), and both BCMA- and GPRC5D-directed immunotherapies defines hepta-refractory MM, a novel end-stage entity. In a multi-center cohort of 37 patients, median overall survival was 12.8 months, with progression-free survival across salvage therapy lines of only 2.7-3.7 months. Whole genome sequencing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.